Study of a new drug for certain lymphomas
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called JNJ-95566692 for people with a type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if the drug can help when no other standard options are available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell lymphoma that has returned or not improved after at least 2 prior treatments, or after 1 treatment if you cannot get standard second-line therapies like CAR-T.
- You should be well enough to carry out daily activities (ECOG score 0 or 1).
- Your lymphoma must be measurable on scans (Lugano criteria).
- You cannot be pregnant or breastfeeding, and if you could become pregnant, you must have a negative pregnancy test and use effective contraception during treatment and for 3 months after.
- You cannot have active lymphoma in the brain or spinal cord.
- You cannot have had a different cancer (except cured skin cancer or early cervix cancer) in the last year, or a solid organ transplant, or autoimmune disease needing strong immune-suppressing medicines in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called GSK5926371 in adults whose B-cell lymphoma (a blood cancer) has come back or stopped responding to previous treatments. The study aims to find out if this drug is safe and whether it can help shrink the cancer.
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
This trial tests a new drug called JNJ-95804306 for people with certain blood cancers (like acute myeloid leukemia, myelodysplastic syndromes, or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The goal is to see if the drug is safe and if it can help.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
This trial tests a new drug called JMT601 for people with a type of B-cell lymphoma that came back or didn't respond to at least two previous treatments. The drug targets a protein on the cancer cells to help your immune system fight the disease.
Hear when a new Lymphoma, Non-Hodgkin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.